PURPOSE:Long-term androgen suppression plus radiotherapy (AS+RT) is standard treatment of high-risk prostate cancer. A randomized trial, Radiation Therapy Oncology Group trial 9902, was undertaken to determine whether adjuvant chemotherapy with paclitaxel, estramustine, and etoposide (TEE) plus AS+RT would improve disease outcomes with acceptable toxicity. METHODS AND MATERIALS: High-risk (prostate-specific antigen 20-100 ng/mL and Gleason score >or=7; or Stage T2 or greater, Gleason score 8, prostate-specific antigen level <100 ng/mL) nonmetastatic prostate cancer patients were randomized to AS+RT (Arm 1) vs. AS+RT plus four cycles of TEE (Arm 2). TEE was delivered 4 weeks after RT. AS continued for 2 years for both treatment arms. RT began after 8 weeks of AS began. RESULTS: The Radiation Therapy Oncology Group 9902 trial opened January 11, 2000. Excess thromboembolic toxicity was noted, leading to study closure October 4, 2004. A total of 397 patients were accrued, and the data for 381 were analyzable. An acute and long-term toxicity analysis was performed. The worst overall toxicities during treatment were increased for Arm 2. Of the 192 patients, 136 (71%) on Arm 2 had RTOG Grade 3 or greater toxicity compared with 70 (37%) of 189 patients on Arm 1. Statistically significant increases in hematologic toxicity (p < 0.0001) and gastrointestinal toxicity (p = 0.017) but not genitourinary toxicity (p = 0.07) were noted during treatment. Two Grade 5 complications related to neutropenic infection occurred in Arm 2. Three cases of myelodysplasia/acute myelogenous leukemia were noted in Arm 2. At 2 and 3 years after therapy completion, excess long-term toxicity was not observed in Arm 2. CONCLUSION:TEE was associated with significantly increased toxicity during treatment. The toxicity profiles did not differ at 2 and 3 years after therapy. Toxicity is an important consideration in the design of trials using adjuvant chemotherapy for prostate cancer.
RCT Entities:
PURPOSE: Long-term androgen suppression plus radiotherapy (AS+RT) is standard treatment of high-risk prostate cancer. A randomized trial, Radiation Therapy Oncology Group trial 9902, was undertaken to determine whether adjuvant chemotherapy with paclitaxel, estramustine, and etoposide (TEE) plus AS+RT would improve disease outcomes with acceptable toxicity. METHODS AND MATERIALS: High-risk (prostate-specific antigen 20-100 ng/mL and Gleason score >or=7; or Stage T2 or greater, Gleason score 8, prostate-specific antigen level <100 ng/mL) nonmetastatic prostate cancerpatients were randomized to AS+RT (Arm 1) vs. AS+RT plus four cycles of TEE (Arm 2). TEE was delivered 4 weeks after RT. AS continued for 2 years for both treatment arms. RT began after 8 weeks of AS began. RESULTS: The Radiation Therapy Oncology Group 9902 trial opened January 11, 2000. Excess thromboembolic toxicity was noted, leading to study closure October 4, 2004. A total of 397 patients were accrued, and the data for 381 were analyzable. An acute and long-term toxicity analysis was performed. The worst overall toxicities during treatment were increased for Arm 2. Of the 192 patients, 136 (71%) on Arm 2 had RTOG Grade 3 or greater toxicity compared with 70 (37%) of 189 patients on Arm 1. Statistically significant increases in hematologic toxicity (p < 0.0001) and gastrointestinal toxicity (p = 0.017) but not genitourinary toxicity (p = 0.07) were noted during treatment. Two Grade 5 complications related to neutropenic infection occurred in Arm 2. Three cases of myelodysplasia/acute myelogenous leukemia were noted in Arm 2. At 2 and 3 years after therapy completion, excess long-term toxicity was not observed in Arm 2. CONCLUSION: TEE was associated with significantly increased toxicity during treatment. The toxicity profiles did not differ at 2 and 3 years after therapy. Toxicity is an important consideration in the design of trials using adjuvant chemotherapy for prostate cancer.
Authors: M Kamrava; A H Kesarwala; R A Madan; E Lita; A Kaushal; K-Y Tsang; D J Poole; S M Steinberg; T Ferrara; W Dahut; J Schlom; J L Gulley Journal: Prostate Cancer Prostatic Dis Date: 2012-03-06 Impact factor: 5.554
Authors: Madeleine S Q Kortenhorst; Michel D Wissing; Ronald Rodríguez; Sushant K Kachhap; Judith J M Jans; Petra Van der Groep; Henk M W Verheul; Anuj Gupta; Paul O Aiyetan; Elsken van der Wall; Michael A Carducci; Paul J Van Diest; Luigi Marchionni Journal: Epigenetics Date: 2013-07-19 Impact factor: 4.528
Authors: Javier Puente; Enrique Grande; Ana Medina; Pablo Maroto; Nuria Lainez; Jose Angel Arranz Journal: Ther Adv Med Oncol Date: 2017-03-01 Impact factor: 8.168
Authors: Seth A Rosenthal; Daniel Hunt; A Oliver Sartor; Kenneth J Pienta; Leonard Gomella; David Grignon; Raghu Rajan; Kevin J Kerlin; Christopher U Jones; Michael Dobelbower; William U Shipley; Kenneth Zeitzer; Daniel A Hamstra; Viroon Donavanik; Marvin Rotman; Alan C Hartford; Jeffrey Michalski; Michael Seider; Harold Kim; Deborah A Kuban; Jennifer Moughan; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2015-07-21 Impact factor: 7.038
Authors: Gregory P Swanson; William E Jones; Chul S Ha; Carol A Jenkins; Addanki Pratap Kumar; Joseph Basler Journal: Phytother Res Date: 2014-09-09 Impact factor: 5.878
Authors: Matthew J Ferris; Yuan Liu; Jingning Ao; Jim Zhong; Mustafa Abugideiri; Theresa W Gillespie; Bradley C Carthon; Mehmet A Bilen; Omer Kucuk; Ashesh B Jani Journal: Urol Oncol Date: 2018-10-09 Impact factor: 3.498